cl-387626 and Disease-Models--Animal

cl-387626 has been researched along with Disease-Models--Animal* in 2 studies

Other Studies

2 other study(ies) available for cl-387626 and Disease-Models--Animal

Article	Year
Inhalation efficacy of RFI-641 in an African green monkey model of RSV infection. Journal of medical primatology, 2003, Volume: 32, Issue:2 Human respiratory syncytial virus (RSV) is a major cause of acute upper and lower respiratory tract infections. RFI-641 is a novel RSV fusion inhibitor with potent in vitro activity. In vivo efficacy of RFI was determined in an African green monkey model of RSV infection involving prophylactic and therapeutic administration by inhalation exposure. Inhalation was with an RFI-641 nebulizer reservoir concentration of 15 mg/ml for 15 minutes (short exposure) or 2 hours (long exposure). Efficacy and RFI-641 exposure was determined by collection of throat swabs, nasal washes and bronchial alveolar lavage (BAL) on selected days. The short-exposure group (15 minutes) exhibited no effect on the nasal, throat or BAL samples. The throat and nasal samples for the long-exposure group failed to show a consistent reduction in viral titers. RFI-641 2 hours exposure-treated monkeys showed a statistically significantly log reduction for BAL samples of 0.73-1.34 PFU/ml (P-value 0.003) over all the sampling days. Analysis indicates that the long-exposure group titer was lower than the control titer on day 7 and when averaged across days. The results of this study demonstrate the ability of RFI-641 to reduce the viral load of RSV after inhalation exposure in the primate model of respiratory infection. Topics: Administration, Inhalation; Aerosols; Animals; Bronchoalveolar Lavage Fluid; Chlorocebus aethiops; Disease Models, Animal; Female; Male; Molecular Structure; Respiratory Syncytial Virus Infections; Respiratory Syncytial Viruses; Sulfonamides; Triazines	2003
The discovery of RFI-641 as a potent and selective inhibitor of the respiratory syncytial virus. Bioorganic & medicinal chemistry letters, 2001, Apr-23, Volume: 11, Issue:8 The design and synthesis of a new potent and selective inhibitor of the respiratory syncytial virus are described. This compound, RFI-641, emerged from analysis of the structure-activity relationship in a series of biphenyl triazine anionic compounds possessing specific anti-RSV activity. The key synthetic step involves coupling of diaminobiphenyl 11 with two equivalents of chlorotriazine 10 under microwave conditions. RFI-641 inhibited RSV in vitro and in vivo models. Topics: Animals; Antiviral Agents; Cells, Cultured; Chlorocebus aethiops; Cytomegalovirus; Disease Models, Animal; Drug Design; Enzyme-Linked Immunosorbent Assay; Herpesvirus 1, Human; Humans; Inhibitory Concentration 50; Mice; Nose; Rats; Respiratory Syncytial Virus Infections; Respiratory Syncytial Viruses; Sensitivity and Specificity; Structure-Activity Relationship; Sulfonamides; Triazenes; Triazines	2001

Article

Year

Inhalation efficacy of RFI-641 in an African green monkey model of RSV infection.

Journal of medical primatology, 2003, Volume: 32, Issue:2

Human respiratory syncytial virus (RSV) is a major cause of acute upper and lower respiratory tract infections. RFI-641 is a novel RSV fusion inhibitor with potent in vitro activity. In vivo efficacy of RFI was determined in an African green monkey model of RSV infection involving prophylactic and therapeutic administration by inhalation exposure. Inhalation was with an RFI-641 nebulizer reservoir concentration of 15 mg/ml for 15 minutes (short exposure) or 2 hours (long exposure). Efficacy and RFI-641 exposure was determined by collection of throat swabs, nasal washes and bronchial alveolar lavage (BAL) on selected days. The short-exposure group (15 minutes) exhibited no effect on the nasal, throat or BAL samples. The throat and nasal samples for the long-exposure group failed to show a consistent reduction in viral titers. RFI-641 2 hours exposure-treated monkeys showed a statistically significantly log reduction for BAL samples of 0.73-1.34 PFU/ml (P-value 0.003) over all the sampling days. Analysis indicates that the long-exposure group titer was lower than the control titer on day 7 and when averaged across days. The results of this study demonstrate the ability of RFI-641 to reduce the viral load of RSV after inhalation exposure in the primate model of respiratory infection.

Topics: Administration, Inhalation; Aerosols; Animals; Bronchoalveolar Lavage Fluid; Chlorocebus aethiops; Disease Models, Animal; Female; Male; Molecular Structure; Respiratory Syncytial Virus Infections; Respiratory Syncytial Viruses; Sulfonamides; Triazines

2003

The discovery of RFI-641 as a potent and selective inhibitor of the respiratory syncytial virus.

Bioorganic & medicinal chemistry letters, 2001, Apr-23, Volume: 11, Issue:8

The design and synthesis of a new potent and selective inhibitor of the respiratory syncytial virus are described. This compound, RFI-641, emerged from analysis of the structure-activity relationship in a series of biphenyl triazine anionic compounds possessing specific anti-RSV activity. The key synthetic step involves coupling of diaminobiphenyl 11 with two equivalents of chlorotriazine 10 under microwave conditions. RFI-641 inhibited RSV in vitro and in vivo models.

Topics: Animals; Antiviral Agents; Cells, Cultured; Chlorocebus aethiops; Cytomegalovirus; Disease Models, Animal; Drug Design; Enzyme-Linked Immunosorbent Assay; Herpesvirus 1, Human; Humans; Inhibitory Concentration 50; Mice; Nose; Rats; Respiratory Syncytial Virus Infections; Respiratory Syncytial Viruses; Sensitivity and Specificity; Structure-Activity Relationship; Sulfonamides; Triazenes; Triazines

2001